Deal Statistics Quarterly, Q3 2000
Executive Summary
In Vivo presents the second installment of a new quarterly feature--a statistical review compiled from Windhover's Strategic Transactions Database of the deal activity within the pharmaceuticals, biotechnology, medical device and in vitro diagnostics industries.
You may also be interested in...
COVID-19 Vaccine Strain Updates Don’t Exactly Fit Flu Model
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
Lundbeck Ready To Funnel 2022 Growth Into Expected Alzheimer’s Agitation Launch
The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.
FDA Suggests Sharing OTC COVID-19 Test Results With NIH Program To Help Health Agencies Plan
FDA releases information about reporting results of OTC at-home COVID-19 antigen tests, as well as recommendations on who should get tested, when and how often.